Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

Watchlist Manager
Zentalis Pharmaceuticals Inc Logo
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Watchlist
Price: 1.3 USD -5.8% Market Closed
Market Cap: 93.5m USD

EV/EBITDA
Enterprise Value to EBITDA

1.2
Current
-2.4
Median
4.6
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
1.2
=
Enterprise Value
-238.9m USD
/
EBITDA
-198.1m USD
EBITDA Growth EV/EBITDA to Growth
US
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Average EV/EBITDA: 13.1
1.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 255.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.6
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -567 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -681 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
0.9
2-Years Forward
EV/EBITDA
0.8
3-Years Forward
EV/EBITDA
0.8